◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › PRME

Prime Medicine, Inc. (PRME) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-09

Prime Medicine, Inc. (PRME) operates in the Biotechnology industry and is headquartered in Cambridge, United States with about 146 employees. Its market capitalization is roughly $764 million. In the fiscal year ended 2025-12-31, PRME reported $5M in revenue and ($201M) in net income.

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States.

Interactive charts & full statements → Open the PRME valuation workbench →

PRME Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$5M$3M$0M$0M
Operating Income (EBIT)($208M)($202M)($191M)($116M)
Net Income($201M)($196M)($198M)($122M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PRME Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Revenue$1M$1M$1M$1M$2M
Operating Income (EBIT)($51M)($49M)($54M)($53M)($52M)
Net Income($49M)($46M)($51M)($53M)($52M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PRME Free Cash Flow History

PRME Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$343M$298M$194M$360M
Total Liabilities$222M$144M$61M$44M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PRME viewer.

Other Companies in Biotechnology

← PRMBAll stocksPROF →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.